Clinical Trial Update: Defining the Potency of DTG/3TC for Suppressed HIV Patients in Real-life: the DUALING Study

View source ↗

Summary

A clinical trial update focusing on the potency of the DTG/3TC fixed-dose combination for people with suppressed HIV in real-world settings (the DUALING study).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection

Drugs mentioned

• Dovato (dolutegravir/lamivudine)
• Juluca (dolutegravir + rilpivirine)

Snippet

Sponsor: Erasmus Medical Center | Conditions: Hiv | Status: ACTIVE_NOT_RECRUITING | Results posted: 2024-12-20